Literature DB >> 25016198

Region specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein.

Sudhakar Raja Subramaniam1, Laurent Vergnes2, Nicholas R Franich3, Karen Reue4, Marie-Francoise Chesselet5.   

Abstract

Parkinson's disease (PD) is characterized by the progressive degeneration of nigrostriatal dopaminergic neurons leading to motor deficits. The mechanisms underlying the preferential vulnerability of nigrostriatal dopaminergic neurons in PD remain poorly understood. Recent evidence supports a role for mitochondrial dysfunction and increased oxidative stress in PD pathogenesis. Genetic and pathological studies also point to alpha-synuclein as a critical factor in both familial and sporadic forms of the disease; alpha-synuclein pathology affects mitochondrial function but is widespread in PD brain, raising the question of its role in the greater vulnerability of nigrostriatal neurons in PD. We have examined mitochondrial function and oxidative damage in mice overexpressing human wild type alpha-synuclein broadly throughout the nervous system under the Thy1 promoter (Thy1-aSyn mice) between 4 and 8months of age. Similar levels of alpha-synuclein accumulation in mitochondria were detected in the ventral midbrain, striatum and cortex of Thy1-aSyn mice. However, analysis of mitochondrial respiration using Seahorse XF analyzer showed defects in mitochondrial respiratory complexes I, II, IV and V specifically in the midbrain, and IV and V in the striatum, of Thy1-aSyn mice compared to wild type littermates; mitochondrial complex I activity assay by ELISA confirmed a 40% inhibition specifically in the ventral midbrain. Mitochondrial dysfunction can contribute to oxidative stress and we observed a 40% increase in 4-hydroxynenal and 2-fold increase in malondialdehyde levels, indicative of a high level of lipid peroxidation, specifically in the ventral midbrain of Thy1-aSyn mice. The levels of peroxiredoxin 2, a neuronal antioxidant enzyme that is involved in removal of H2O2 and other toxic peroxides were decreased in the midbrain whereas its oxidized form increased 4-fold, suggesting that antioxidant defenses were compromised in this region. In contrast, peroxiredoxin 2 increased in the striatum and cortex, which may contribute to their protection in the presence of high levels of alpha-synuclein. Thus, in mice over-expressing alpha-synuclein, mitochondrial dysfunction occurred preferentially in nigrostriatal dopaminergic neurons many months before striatal dopamine loss occurs at 14months of age. This may contribute to a higher level of oxidative stress that overwhelms antioxidant defense in these neurons, leading to their increased vulnerability in PD.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alpha synuclein; Lipid peroxidation; Mitochondrial dysfunction; Oxidative damage; Peroxiredoxin

Mesh:

Substances:

Year:  2014        PMID: 25016198      PMCID: PMC4205109          DOI: 10.1016/j.nbd.2014.06.017

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  49 in total

Review 1.  Mitochondrial quality control and dynamics in Parkinson's disease.

Authors:  Melissa K McCoy; Mark R Cookson
Journal:  Antioxid Redox Signal       Date:  2011-07-07       Impact factor: 8.401

2.  Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortium.

Authors:  V McGuire; S K Van Den Eeden; C M Tanner; F Kamel; D M Umbach; K Marder; R Mayeux; B Ritz; G W Ross; H Petrovitch; B Topol; R A Popat; S Costello; A D Manthripragada; A Southwick; R M Myers; L M Nelson
Journal:  J Neurol Sci       Date:  2011-06-12       Impact factor: 3.181

3.  Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's disease.

Authors:  Almas Siddiqui; Shankar J Chinta; Jyothi K Mallajosyula; Subramanian Rajagopolan; Ingrid Hanson; Anand Rane; Simon Melov; Julie K Andersen
Journal:  Free Radic Biol Med       Date:  2012-06-15       Impact factor: 7.376

Review 4.  A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice.

Authors:  Marie-Francoise Chesselet; Franziska Richter; Chunni Zhu; Iddo Magen; Melanie B Watson; Sudhakar R Subramaniam
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

5.  Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1α transcription.

Authors:  Scott D Ryan; Nima Dolatabadi; Shing Fai Chan; Xiaofei Zhang; Mohd Waseem Akhtar; James Parker; Frank Soldner; Carmen R Sunico; Saumya Nagar; Maria Talantova; Brian Lee; Kevin Lopez; Anthony Nutter; Bing Shan; Elena Molokanova; Yaoyang Zhang; Xuemei Han; Tomohiro Nakamura; Eliezer Masliah; John R Yates; Nobuki Nakanishi; Aleksander Y Andreyev; Shu-ichi Okamoto; Rudolf Jaenisch; Rajesh Ambasudhan; Stuart A Lipton
Journal:  Cell       Date:  2013-11-27       Impact factor: 41.582

6.  Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells.

Authors:  Shaik Shavali; Holly M Brown-Borg; Manuchair Ebadi; James Porter
Journal:  Neurosci Lett       Date:  2008-05-08       Impact factor: 3.046

Review 7.  Mitochondrial dysfunction and oxidative stress in Parkinson's disease.

Authors:  Sudhakar Raja Subramaniam; Marie-Francoise Chesselet
Journal:  Prog Neurobiol       Date:  2013-04-30       Impact factor: 11.685

8.  TOM40 mediates mitochondrial dysfunction induced by α-synuclein accumulation in Parkinson's disease.

Authors:  Andreas Bender; Paula Desplats; Brian Spencer; Edward Rockenstein; Anthony Adame; Matthias Elstner; Christoph Laub; Sarina Mueller; Andrew O Koob; Michael Mante; Emily Pham; Thomas Klopstock; Eliezer Masliah
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

9.  High throughput microplate respiratory measurements using minimal quantities of isolated mitochondria.

Authors:  George W Rogers; Martin D Brand; Susanna Petrosyan; Deepthi Ashok; Alvaro A Elorza; David A Ferrick; Anne N Murphy
Journal:  PLoS One       Date:  2011-07-25       Impact factor: 3.240

10.  Impairment of mitochondria in adult mouse brain overexpressing predominantly full-length, N-terminally acetylated human α-synuclein.

Authors:  Theodore A Sarafian; Christopher M Ryan; Puneet Souda; Eliezer Masliah; Upendra K Kar; Harry V Vinters; Gary W Mathern; Kym F Faull; Julian P Whitelegge; Joseph B Watson
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more
  47 in total

Review 1.  α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease.

Authors:  Sushil K Singh; Aloke Dutta; Gyan Modi
Journal:  Future Med Chem       Date:  2017-06-20       Impact factor: 3.808

2.  Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type α-synuclein.

Authors:  Sudhakar R Subramaniam; Iddo Magen; Nicholas Bove; Chunni Zhu; Vincent Lemesre; Garima Dutta; Chris Jean Elias; Henry A Lester; Marie-Francoise Chesselet
Journal:  Neurobiol Dis       Date:  2018-06-01       Impact factor: 5.996

3.  Exacerbation of sensorimotor dysfunction in mice deficient in Atp13a2 and overexpressing human wildtype alpha-synuclein.

Authors:  Emily R Dirr; Osunde R Ekhator; Rachel Blackwood; John G Holden; Eliezer Masliah; Patrick J Schultheis; Sheila M Fleming
Journal:  Behav Brain Res       Date:  2018-02-03       Impact factor: 3.332

4.  Enhanced mitochondrial inhibition by 3,4-dihydroxyphenyl-acetaldehyde (DOPAL)-oligomerized α-synuclein.

Authors:  Theodore A Sarafian; Amneh Yacoub; Anastasia Kunz; Burkan Aranki; Grigor Serobyan; Whitaker Cohn; Julian P Whitelegge; Joseph B Watson
Journal:  J Neurosci Res       Date:  2019-08-16       Impact factor: 4.164

5.  A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein.

Authors:  Franziska Richter; Sudhakar R Subramaniam; Iddo Magen; Patrick Lee; Jane Hayes; Aida Attar; Chunni Zhu; Nicholas R Franich; Nicholas Bove; Krystal De La Rosa; Jacky Kwong; Frank-Gerrit Klärner; Thomas Schrader; Marie-Françoise Chesselet; Gal Bitan
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 6.  The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.

Authors:  Noémie Cresto; Camille Gardier; Francesco Gubinelli; Marie-Claude Gaillard; Géraldine Liot; Andrew B West; Emmanuel Brouillet
Journal:  Eur J Neurosci       Date:  2018-10-24       Impact factor: 3.386

7.  Individual Amino Acid Supplementation Can Improve Energy Metabolism and Decrease ROS Production in Neuronal Cells Overexpressing Alpha-Synuclein.

Authors:  Vedad Delic; Jeddidiah W D Griffin; Sandra Zivkovic; Yumeng Zhang; Tam-Anh Phan; Henry Gong; Dale Chaput; Christian Reynes; Vinh B Dinh; Josean Cruz; Eni Cvitkovic; Devon Placides; Ernide Frederic; Hamed Mirzaei; Stanley M Stevens; Umesh Jinwal; Daniel C Lee; Patrick C Bradshaw
Journal:  Neuromolecular Med       Date:  2017-06-15       Impact factor: 3.843

8.  Glucose Metabolism and AMPK Signaling Regulate Dopaminergic Cell Death Induced by Gene (α-Synuclein)-Environment (Paraquat) Interactions.

Authors:  Annadurai Anandhan; Shulei Lei; Roman Levytskyy; Aglaia Pappa; Mihalis I Panayiotidis; Ronald L Cerny; Oleh Khalimonchuk; Robert Powers; Rodrigo Franco
Journal:  Mol Neurobiol       Date:  2016-06-20       Impact factor: 5.590

Review 9.  New insights on Parkinson's disease genes: the link between mitochondria impairment and neuroinflammation.

Authors:  Dorit Trudler; Yuval Nash; Dan Frenkel
Journal:  J Neural Transm (Vienna)       Date:  2015-04-17       Impact factor: 3.575

Review 10.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.